ArticleCancer medicine2025
The Influence of Performance Status, Inflammation, and Nutrition on the Impact of SGLT2 Inhibitors on Cancer Outcomes.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Metabolic Adaptations in Cancer Progression: Optimization Strategies and Therapeutic Targets.Cancers · 2025Review
- Association of sodium-glucose cotransporter-2 inhibitor use and mortality in patients with endometrial cancer: a retrospective cohort study.BMC cancer · 2025Article
- Potential anticancer effects of sodium-glucose cotransporter protein 2 (SGLT2) inhibitors Canagliflozin and Dapagliflozin.Cancer chemotherapy and pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSodium-glucose-linked transporter 2 inhibitors (SGLT2i) may have antitumor effects. Previous studies analyzing their role in mortality and progression did not account for potential confounders, including cancer treatment, performance status, inflammatory markers, and nutritional status. This study aims to evaluate the impact of SGLT2i treatment on mortality and progression while considering these potential confounders.
methodsA retrospective cohort study was conducted. A total of 526 patients with cancer (302 women, mean age 64 years, range 40-79 years) were divided into two cohorts based on whether they were taking SGLT2i at the time of their cancer diagnosis and followed for 1 year or until death. All patients on SGLT2i were taking these drugs at standard clinical doses. Additional data collected included basic demographic variables, metabolic and lifestyle characteristics, cancer treatment received, performance status, inflammatory markers, and nutritional status. The primary endpoints were mortality and progression.
resultsPatients taking SGLT2i at the time of cancer diagnosis (n = 41) were more likely to have type 2 diabetes, to be male, to be ever-smokers, and to be older than patients not taking SGLT2i. In univariate analyses, SGLT2i treatment at the time of cancer diagnosis was not associated with mortality or cancer progression. Instead, mortality and cancer progression were positively associated with a diagnosis of T2D, male sex, older age, heavy alcohol drinking, ever-smoker status, poor performance status, increased inflammation, malnutrition, tumor site, cancer stage, and lack of cancer treatment. After adjusting for these potential confounders, SGLT2i treatment was not significantly associated with mortality or cancer progression.
conclusionsOur results suggest that the impact of SGLT2i treatment on cancer outcomes is limited under standard clinical dosing conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.